Coronary artery disease is the leading cause of death worldwide, and its main pathological substrate is represented by atherosclerosis. Inflammation is a major promoter of the atherosclerotic process and is involved in both the initiation and progression of atherosclerosis, as well as in the occurrence of fatal complications. Until the present moment, Colchicine Cardiovascular Outcomes Trial is the largest trial to demonstrate a major benefit of low-dose colchicine on major adverse cardiac events in patients with recent myocardial infarction (MI), but the mechanisms behind this relation are not completely known. The purpose of this review is to emphasize the possible pathways through which colchicine improves the clinical outcomes in the acute setting of acute coronary syndromes by referring to the results of the studies published in the past 5 years. Aside from its stated systemic anti-inflammatory effect, colchicine could be a valuable addition to the therapeutic approach of acute MI by reducing the infarct size, stabilizing the coronary plaque, as well as reducing platelet aggregation. Moreover, colchicine may improve endothelial function, reduce the transcoronary release of cytokines, and prevent a rise in inflammatory markers after percutaneous coronary intervention, thus diminishing the residual inflammatory risk.
NowbarANGittoMHowardJPFrancisDPAl-LameeR. Mortality from ischemic heart disease. 2019;12:e005375.
2.
CrittendenDBLehmannRASchneckL, et al.Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. The Journal of rheumatology. 2012;39:1458–64.
3.
DemidowichAPLevineJAOnyekabaGI, et al.Effects of colchicine in adults with metabolic syndrome: a pilot randomized controlled trial. 2019;21:1642–51.
4.
NidorfSMEikelboomJWBudgeonCAThompsonPL. Low-dose colchicine for secondary prevention of cardiovascular disease. Journal of the American College of Cardiology. 2013;61:404–10.
5.
TardifJCKouzSWatersDD, et al.Efficacy and safety of low-dose colchicine after Myocardial infarction. The New England journal of medicine. 2019;381:2497–505.
6.
ShaoCWangJTianJTangY-d. Coronary artery disease: from mechanism to clinical practice. In: WangM, editor. Coronary Artery Disease: Therapeutics and Drug Discovery. Singapore: Springer Singapore; 2020. p. 1–36.
7.
WolfDLeyK. Immunity and Inflammation in Atherosclerosis. 2019;124:315–27.
8.
RidkerPMLüscherTF. Anti-inflammatory therapies for cardiovascular disease. European heart journal. 2014;35:1782–91.
9.
QuillardTFranckGMawsonTFolcoELibbyP. Mechanisms of erosion of atherosclerotic plaques. 2017;28:434–41.
10.
Hernández-AguileraAFiblaMCabréN, et al.Chemokine (C-C motif) ligand 2 and coronary artery disease: tissue expression of functional and atypical receptors. Cytokine. 2020;126:154923.
11.
ZhuYXianXWangZ, et al.Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018;8:80.
12.
KaptogeSSeshasaiSRKGaoP, et al.Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. European heart journal. 2013;35:578–89.
13.
RidkerPMMacFadyenJGGlynnRJBradwinGHasanAARifaiN.Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. European heart journal. 2020;41:2952–61.
14.
MunjalAKhandiaR. Chapter Three - Atherosclerosis: orchestrating cells and biomolecules involved in its activation and inhibition. In: DonevR, editor. Advances in Protein Chemistry and Structural Biology: Academic Press; 2020. p. 85–122.
15.
DöringYVorstEPCvdDucheneJ, et al.CXCL12 derived from endothelial cells promotes atherosclerosis to drive coronary artery disease. 2019;139:1338–40.
16.
StrowigTHenao-MejiaJElinavEFlavellR. Inflammasomes in health and disease. Nature. 2012;481:278–86.
17.
XiaoBHuangXWangQWuY. Beta-Asarone Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammatory Response and NLRP3 Inflammasome Mediated Pyroptosis. Biological & pharmaceutical bulletin. 2020;43:1046–51.
18.
AfrasyabAQuPZhaoY, et al.Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients. Heart and vessels. 2016;31:1218–29.
19.
VersaciFGaspardoneA. Prevention of restenosis after stenting: the emerging role of inflammation. 2004;15:307–11.
20.
MuratSNYarliogluesMCelikIE, et al.The relationship between lymphocyte-to-monocyte ratio and bare-metal stent in-stent restenosis in patients with stable Coronary artery disease. 2017;23:235–40.
21.
FilatovaAYRomasovIVPotekhinaAV, et al.The incidence and possible predictors of coronary restenosis. Kardiologiia. 2020;60:10–6.
22.
RidkerPM. A Test in context: high-sensitivity C-reactive protein. Journal of the American College of Cardiology. 2016;67:712–23.
23.
LeungYYYao HuiLLKrausVB. Colchicine--Update on mechanisms of action and therapeutic uses. Seminars in arthritis and rheumatism. 2015;45:341–50.
24.
PericoNOstermannDBontempeillM, et al.Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. 1996;7:594–601.
25.
CronsteinBNMoladYReibmanJBalakhaneELevinRIWeissmannG. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. The Journal of clinical investigation. 1995;96:994–1002.
26.
DeftereosSGiannopoulosGPapoutsidakisN, et al.Colchicine and the heart: pushing the envelope. Journal of the American College of Cardiology. 2013;62:1817–25.
27.
ShahBAllenNHarchandaniB, et al.Effect of colchicine on platelet-platelet and Platelet-Leukocyte interactions: a pilot study in healthy subjects. Inflammation. 2016;39:182–9.
28.
AbanonuGBDaskinAAkdoganMFUyarSDemirtuncR. Mean platelet volume and beta-thromboglobulin levels in familial Mediterranean fever: effect of colchicine use?European Journal of Internal Medicine. 2012;23:661–4.
29.
SariIYukselAKozaciD, et al.The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial Mediterranean fever. Inflammation. 2012;35:1191–7.
30.
CimminoGTaralloRConteS, et al.Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascul Pharmacol. 2018;111:62–70.
31.
CirilloPTaglialatelaVPellegrinoG, et al.Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. Journal of Thrombosis and Thrombolysis. 2020;50:468–72.
32.
YueHLiangWGuJ, et al.Comparative transcriptome analysis to elucidate the therapeutic mechanism of colchicine against atrial fibrillation. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2019;119:109422.
33.
HuangCCenCWangCZhanHDingX. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis. 2014;13:67.
34.
KajikawaMHigashiYTomiyamaH, et al.Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. International Journal of Cardiology. 2019;281:35–9.
35.
DeftereosSGiannopoulosGAngelidisC, et al.Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132:1395–403.
36.
RobertsonSMartinezGJPayetCA, et al.Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clinical science (London, England: 1979). 2016;130:1237–46.
37.
MartinezGJRobertsonSBarracloughJ, et al.Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. Journal of the American Heart Association. 2015;4: e002128.
38.
TuckerBKurupRBarracloughJ, et al.Colchicine as a novel therapy for suppressing chemokine production in patients with an acute coronary syndrome: a pilot study. Clinical Therapeutics. 2019;41:2172–81.
39.
GuedeneyPClaessenBEKalkmanDN, et al.Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention. Journal of the American College of Cardiology. 2019;73:2401–9.
40.
ShahBPillingerMZhongH, et al.Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial. Circulation Cardiovascular Interventions. 2020;13: e008717.
41.
VaidyaKArnottCMartinezGJ, et al.Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study. JACC Cardiovascular Imaging. 2018;11:305–16.
42.
BarracloughJYJoglekarMVJanuszewskiAS, et al.A MicroRNA signature in acute coronary syndrome patients and modulation by colchicine. Journal of Cardiovascular Pharmacology and Therapeutics. 2020:1074248420922793.
43.
AkodadMLattucaBNagotN, et al.COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Archives of Cardiovascular Diseases. 2017;110:395–402.
44.
HennessyTSohLBowmanM, et al.The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. American Heart Journal. 2019;215:62–9.
45.
RidkerPMEverettBMThurenT, et al.Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine. 2017;377:1119–31.
46.
FioletATLSilvisMJMOpstalTSJ, et al.Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PloS one. 2020;15:e0237665.
47.
NidorfSMFioletATLMosterdA, et al.Colchicine in Patients with Chronic Coronary Disease. The New England Journal of Medicine. 2020;383:1838–47.
48.
BouabdallaouiNTardifJCWatersDD, et al.Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal. 2020;41:4092–9.
49.
TongDCQuinnSNasisA, et al.Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020;142:1890–900.
50.
XiaMYangXQianC. Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease. Am J Cardiol. 2020;S0002-9149:31174–31177.
51.
ImazioMBobbioMCecchiE, et al.Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012–6.
52.
ImazioMBobbioMCecchiE, et al.Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Archives of Internal Medicine. 2005;165:1987–91.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
